Theageneio Anticancer Hospital of Thessaloniki
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Katodritou, Eirini
EUMELEIA, NCT06636552: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

Recruiting
2
43
Europe
Daratumumab (Subcutaneously)
Hellenic Society of Hematology
Primary Plasma Cell Leukemia
01/29
01/29
EAE116, NCT05147493 / 2021-004895-32: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Not yet recruiting
2
51
Europe
Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide
Hellenic Society of Hematology, Sanofi
Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
12/24
02/25
EAE120, NCT05280275 / 2021-006792-42: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Recruiting
1/2
36
Europe
Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide, Dexamethasone
Hellenic Society of Hematology, GlaxoSmithKline
Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
03/26
03/26
NCT05573802 / 2022-001942-39: A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Recruiting
1/2
36
Europe
Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone, Nirogacestat
Hellenic Society of Hematology, GlaxoSmithKline
Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
10/26
10/26

Download Options